Sandoz Group AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 20K
- Market Cap
- $19B
- Website
- http://www.sandoz.com
Integrated Pharmacokinetics (PK)/efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination with Yervoy®
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-09
- Last Posted Date
- 2024-09-13
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 720
- Registration Number
- NCT06587451
A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 720
- Registration Number
- NCT06159790
- Locations
- 🇬🇪
Sandoz Investigational Site, Tbilisi, Georgia
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 318
- Registration Number
- NCT06153238
- Locations
- 🇷🇴
Sandoz Investigational Site, Bucharest, Romania
Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 38
- Registration Number
- NCT05887843
- Locations
- 🇨🇦
Sandoz Investigational Site, Toronto, Ontario, Canada
Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 562
- Registration Number
- NCT05633771
- Locations
- 🇧🇪
Sandoz Investigational Site Belgium, Bruxelles, Belgium
🇫🇷Sandoz Investigational Site France, Troyes, France
Efficacy and Safety of Azelastine +Mometasone , Nasal Spray, 140 mcg + 50 mcg, (Sandoz d.d., Slovenia) and Momat Rino Advance, Nasal Spray, 140 mcg + 50 mcg, (Glenmark, India) Administered as a Monotherapy to Patients With Seasonal Allergic Rhinitis.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 472
- Registration Number
- NCT05590598
- Locations
- 🇷🇺
Sandoz Investigative Site, Yaroslavl, Russian Federation
Study of the Efficacy and Safety of Broncho-munal®, Capsules, 7 mg for the Treatment of Acute Uncomplicated Respiratory Tract Infections
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 556
- Registration Number
- NCT05588804
- Locations
- 🇷🇺
Sandoz Investigative Site, Saint-Petersburg, Russian Federation
In Vivo Performance of Oral Liquid Formulations of Budesonide in the Fasted State in Healthy Subjects
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 12
- Registration Number
- NCT05429775
- Locations
- 🇬🇧
Sandoz Investigative Site, Nottingham, England, United Kingdom
Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic Rhinitis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 669
- Registration Number
- NCT05311475
- Locations
- 🇵🇱
Sandoz Investigative Site, Wrocław, Poland
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 36
- Registration Number
- NCT05282004
- Locations
- 🇺🇸
Sandoz Investigational Site, Lynchburg, Virginia, United States
© Copyright 2024. All Rights Reserved by MedPath